Inovio Pharmaceuticals Welcomes Nancy Wysenski to Its Board of Directors
March 05 2015 - 8:46AM
Inovio Pharmaceuticals, Inc. (Nasdaq:INO), a leader in the
development of immunotherapies for cancer and infectious diseases,
announced today that Nancy Wysenski joined its Board of Directors.
Ms. Wysenski, a commercial pharmaceutical executive, has over 30
years' experience in the pharmaceutical industry and has launched
numerous new products.
Ms. Wysenski previously served as the Executive Vice President
and Chief Commercial Officer of Vertex Pharmaceuticals, a publicly
traded pharmaceutical company where she led the effort to build the
commercial infrastructure and launched Incivek® and Kalydeco®.
Prior to joining Vertex, Ms. Wysenski held the position of Chief
Operating Officer of Endo Pharmaceuticals, a specialty
pharmaceutical company, where she led sales, marketing, commercial
operations, supply chain management, human resources and various
business development initiatives. Prior to her time at Endo, Ms.
Wysenski participated in the establishment of EMD Pharmaceuticals,
Inc., where she held various leadership positions, including the
role of President and Chief Executive Officer from 2001 to 2006 and
Vice President of Commercial from 1999 to 2001. From 1984 to 1998,
Ms. Wysenski held several sales-focused roles at major
pharmaceutical companies, including Vice President of Field Sales
for Astra Merck, Inc.
Ms. Wysenski is the Founder and Past President of the Research
Triangle Park Chapter of the Healthcare Businesswomen's
Association, a global non-profit organization for which she serves
as a Board Member. She served on the Nominating Committee and
National Advisory Board of the Healthcare Businesswomen's
Association. Ms. Wysenski earned a B.S. in Nursing from Kent State
University and also holds an Executive Masters in Business
Administration from Baldwin Wallace College. Nancy J. Wysenski also
serves on the boards of Alkermes PLC and Tetraphase
Pharmaceuticals.
Dr. J. Joseph Kim, President & CEO of Inovio, said, "Nancy
brings to our Board of Directors her experience and judgment in
growing a pharmaceutical business and launching new products. Her
counsel in these critical areas will support Inovio as we move our
products closer to market."
About Inovio Pharmaceuticals, Inc.
Inovio is revolutionizing the fight against cancer and
infectious diseases. Our immunotherapies uniquely activate
best-in-class immune responses to prevent and treat disease, and
have shown clinically significant efficacy with a favorable safety
profile. With an expanding portfolio of immune therapies, the
company is advancing a growing preclinical and clinical stage
product pipeline. Partners and collaborators include Roche,
MedImmune, University of Pennsylvania, DARPA, Drexel University,
NIH, HIV Vaccines Trial Network, National Cancer Institute, U.S.
Military HIV Research Program, and University of Manitoba. For more
information, visit www.inovio.com.
This press release contains certain forward-looking statements
relating to our business, including our plans to develop
electroporation-based drug and gene delivery technologies and DNA
vaccines, our expectations regarding our research and development
programs and our capital resources. Actual events or results may
differ from the expectations set forth herein as a result of a
number of factors, including uncertainties inherent in pre-clinical
studies, clinical trials and product development programs
(including, but not limited to, the fact that pre-clinical and
clinical results referenced in this release may not be indicative
of results achievable in other trials or for other indications,
that the studies or trials may not be successful or achieve the
results desired, including safety and efficacy for VGX-3100, that
pre-clinical studies and clinical trials may not commence or be
completed in the time periods anticipated, that results from one
study may not necessarily be reflected or supported by the results
of other similar studies and that results from an animal study may
not be indicative of results achievable in human studies), the
availability of funding to support continuing research and studies
in an effort to prove safety and efficacy of electroporation
technology as a delivery mechanism or develop viable DNA vaccines,
our ability to support our broad pipeline of SynCon® active immune
therapy and vaccine products, our ability to advance our portfolio
of immune-oncology products independently, including INO-5150, and
to commence a phase I clinical trial for INO-5150 in the first half
of 2015, the adequacy of our capital resources, the availability or
potential availability of alternative therapies or treatments for
the conditions targeted by the company or its collaborators,
including alternatives that may be more efficacious or
cost-effective than any therapy or treatment that the company and
its collaborators hope to develop, our ability to enter into
partnerships in conjunction with our research and development
programs, evaluation of potential opportunities, issues involving
product liability, issues involving patents and whether they or
licenses to them will provide the company with meaningful
protection from others using the covered technologies, whether such
proprietary rights are enforceable or defensible or infringe or
allegedly infringe on rights of others or can withstand claims of
invalidity and whether the company can finance or devote other
significant resources that may be necessary to prosecute, protect
or defend them, the level of corporate expenditures, assessments of
the company's technology by potential corporate or other partners
or collaborators, capital market conditions, the impact of
government healthcare proposals and other factors set forth in our
Annual Report on Form 10-K for the year ended December 31, 2013,
our Form 10-Q for the quarter ended September 30, 2014, and other
regulatory filings from time to time. There can be no assurance
that any product in Inovio's pipeline will be successfully
developed or manufactured, that final results of clinical studies
will be supportive of regulatory approvals required to market
licensed products, or that any of the forward-looking information
provided herein will be proven accurate.
CONTACT: Investors: Bernie Hertel, Inovio Pharmaceuticals
858-410-3101, bhertel@inovio.com
Media: Jeff Richardson, Inovio Pharmaceuticals
267-440-4211, jrichardson@inovio.com
Inovio Pharmaceuticals (NASDAQ:INO)
Historical Stock Chart
From Mar 2024 to Apr 2024
Inovio Pharmaceuticals (NASDAQ:INO)
Historical Stock Chart
From Apr 2023 to Apr 2024